Skip to main content Back to Top
Advertisement

11/11/2016

Imipenem and Cilastatin Sodium

Products Affected - Description

    • Primaxin injection, Merck, 250 mg/ 250 mg, vial, 25 count, NDC 00006-3514-58
    • Primaxin injection, Merck, 250 mg/250 mg, ADD-Vantage vial, 25 count, NDC 00006-3551-58
    • Primaxin injection, Merck, 500 mg/500 mg, ADD-Vantage vial, 25 count, NDC 00006-3552-59

Reason for the Shortage

    • Fresenius Kabi had imipenem and cilastatin sodium injection on shortage due to increased demand.
    • Hospira had imipenem and cilastatin sodium injection on shortage due to manufacturing delays.
    • Merck has discontinued Primaxin ADD-Vantage vials as well as the 250 mg vials. Merck has Primaxin 500 mg vials available.

Available Products

    • Primaxin injection, Merck, 500 mg/500 mg, vial, 25 count, NDC 00006-3516-59
    • Imipenem and Cilastatin Sodium injection, Fresenius Kabi, 250 mg/250 mg, vial, 10 count, NDC 63323-0349-20
    • Imipenem and Cilastatin Sodium injection, Fresenius Kabi, 250 mg/250 mg, vial, 25 count, NDC 63323-0349-25
    • Imipenem and Cilastatin Sodium injection, Fresenius Kabi, 500 mg/500 mg, vial, 10 count, NDC 63323-0322-20
    • Imipenem and Cilastatin Sodium injection, Fresenius Kabi, 500 mg/500 mg, vial, 25 count, NDC 63323-0322-25
    • Imipenem and Cilastatin Sodium injection, Pfizer, 250 mg/ 250 mg, vial, 25 count, NDC 00409-3508-01
    • Imipenem and Cilastatin Sodium injection, Pfizer, 500 mg/500 mg, vial, 25 count, NDC 00409-3507-01

Estimated Resupply Dates

    • All marketed presentations are available.

Updated

Updated November 11, 2016 by Michelle Wheeler, PharmD, Drug Information Specialist. Created May 13, 2015 by Jane Chandramouli, PharmD, Drug Information Specialist. Copyright 2017, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

This information is provided through the support of Vizient to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Vizient, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Vizient, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Vizient, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins